16 February 2018
Nigeria is a mission-critical country in efforts to end epidemics. It has the largest malaria burden of any country in the world, with 30 percent of global malaria deaths. Nigeria is number two for HIV globally and seventh for TB burden. We cannot succeed in ending epidemics without delivering significant results in Nigeria. Yet Nigeria is also a complex and challenging operating environment.
Despite challenges, Nigeria has made progress against HIV, TB and malaria. Programs supported by the Global Fund have saved the lives of 1.7 million people in Nigeria, as of end 2016. Between 2000 and 2016, deaths from malaria dropped by 43 percent. Incidence of HIV declined by 37 percent from 2000 to 2016. With the support of the Global Fund, Nigeria passed the 1 million mark for people on ART in 2017. In addition, in 2017, the Global Fund financed the distribution of 14 million mosquito nets in six states over a five-month period, covering an estimated 28 million beneficiaries.
This follow-up audit report clearly demonstrates that the Global Fund together with its country partners have achieved rapid and significant progress since 2015, when a previous audit was conducted. The portfolio is now managed under a strengthened risk management and assurance framework and is on a better trajectory for enabling the country deliver improved programmatic results. The audit takes a sharp view of progress in the areas where deficiencies were previously identified and highlights some specific gaps and key areas requiring further improvement. The Secretariat is already taking responsive action that will further improve grant implementation.
Equally important, the Government of Nigeria has now fully repaid to the Global Fund all amounts deemed recoverable, as identified in the May 2016 OIG Audit and Investigation reports, which we hope will allow us to accelerate the positive trajectory in our partnership to end the epidemics in Nigeria.
I want to highlight some important improvements since the last audit:
The Global Fund Secretariat continues to invest significant time, resources and initiatives to ensure an effective and sustainable response to HIV, TB, and malaria in Nigeria. Not all of these yielded measurable results during the period covered by the follow-up audit, but they will represent important advances as we look forward to our medium-term goals.
In summary, I am pleased this report provides evidence of the significant progress made during the 16 months between the release of the 2016 Audit and the end of the current audit’s review period.
Respectfully,
Marijke Wijnroks